Abstract 15477: Endothelial Cells Overexpressing Interleukin-8 Receptors are Renoprotective in Rats With Acute Kidney Injury
Introduction: In ischemia-reperfusion acute kidney injury (AKI) interleukin-8 (IL8) attracts neutrophils to the site of injury. Neutrophils interact with the damaged endothelium triggering the pro-inflammatory response that prolongs the underperfused state of the kidney and exacerbates injury.
Hypothesis: We tested the hypothesis that intravenous transfusion of rat aortic endothelial cells (ECs) transduced with IL8 receptors (IL8RA/RB-ECs) ameliorates renal dysfunction and promotes structural recovery of the kidney post AKI.
Methods and Results: Male Sprague-Dawley rats were subjected to sham surgery or AKI by clamping the left renal artery for 45 min and removing the right kidney. At time of reperfusion, 1.5x106 IL8RA/RB-ECs, ECs with empty adenoviral vector (AdNull-ECs), or vehicle were infused in the femoral vein. At 24 hrs after AKI, serum creatinine increased ~ 10 fold in the vehicle-treated group and then decreased towards baseline. IL8RA/RB-ECs but not AdNull-ECs significantly blunted the rise in serum creatinine (Fig) and decreased the local expression in the kidney and the circulating levels of inflammatory mediators at 24 hrs after AKI. At 6 wks after AKI, vehicle-treated rats had significant albuminuria compared to sham controls and EC treatment decreased albuminuria by ~65% (Fig). Stained kidney sections at 6 wks after AKI showed that vehicle-treated rats had increased interstitial collagen and decreased capillary density compared to sham controls. IL-8RA/RB-ECs were more effective at reducing interstitial collagen staining than AdNull-ECs. IL8RA/RB-ECs but not AdNull-ECs increased capillary density compared to vehicle (Fig).
Conclusions: Following ischemia-reperfusion AKI, ECs equipped with IL8 receptors are attracted to the site of injury in order to inhibit inflammation, accelerate tissue repair, and preserve renal function. Our innovative cell-based strategy holds promise for improving outcomes after AKI.
Author Disclosures: D. Xing: None. S. Giordano: None. Y. Guo: None. S. Oparil: None. Y. Chen: None. P. Sanders: None.
- © 2015 by American Heart Association, Inc.